Clinical Trials
13 trialsNCT06295809 2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT06624644 2026-04-22
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT06947928 2026-04-17
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
Phase 2/3 Recruiting
NCT06581406 2026-04-02
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune, Inc.
Phase 2/3 Recruiting
NCT05987332 2026-02-17
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
IDEAYA Biosciences
Phase 2/3 Active not recruiting
NCT03470922 2025-09-09
RELATIVITY-047
Bristol-Myers Squibb
Phase 2/3 Active not recruiting
NCT04695977 2025-09-05
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Regeneron Pharmaceuticals
Phase 2/3 Terminated
NCT03552549 2019-07-24
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT03116698 2019-04-24
A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period
Dr. Reddy's Laboratories Limited
Phase 2/3 Completed
NCT03070691 2017-05-05
Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Novartis
Phase 2/3 Withdrawn
NCT02829775 2017-01-09
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Hoffmann-La Roche
Phase 2/3 Completed
NCT01729663 2015-09-02
Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients
Laboratorio Pablo Cassará S.R.L.
Phase 2/3 Unknown
NCT00055562 2005-06-24
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Celgene
Phase 2/3 Completed